中文名称: | PPADS tetrasodium | ||||
---|---|---|---|---|---|
英文名称: | PPADS tetrasodium | ||||
别名: | PPADS tetrasodium 4-[[4-Formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium salt | ||||
CAS No: | 192575-19-2 | 分子式: | C14H10N3Na4O12PS2 | 分子量: | 599.3 |
CAS No: | 192575-19-2 | ||||
分子式: | C14H10N3Na4O12PS2 | ||||
分子量: | 599.3 |
基本信息
产品编号: |
P11285 |
||||
产品名称: |
PPADS tetrasodium |
||||
CAS: |
192575-19-2 |
储存条件 |
粉末 |
-20℃ |
四年 |
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量: |
599.30 |
-20℃ |
1个月 |
||
化学名: |
4-[[4-Formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]-2-pyridinyl]azo]-1,3-benzenedisulfonic acid tetrasodium salt |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
|
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
|
||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
1.6686mL |
8.3431mL |
16.6861mL |
5mM |
0.3337mL |
1.6686mL |
3.3372mL |
10mM |
0.1669mL |
0.8343mL |
1.6686mL |
生物活性
产品描述 |
一种非选择性P2X受体拮抗剂 |
||
靶点 |
P2X Receptor |
Na+/Ca2+ Exchanger |
|
体外研究 |
PPADS tetrasodiuma (1-30μM;10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.PPADS tetrasodiuma is effective at other native and recombinant P2XRs.At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and is highest at the hP2X1,-2,-3,-5,and -7Rs with an IC50 of ~1-3 and ~30μM for the hP2X4R. |
||
体内研究 |
PPADS tetrasodiuma (15-60mg/100g body weight (BW);i.p.;every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis. |
||
Animal Model: |
Male Sprague-Dawley ratsweighing 160 to 200g (anti-Thy1 disease mode) |
||
Dosage: |
15mg/100g BW,30mg/100g BW,60mg/100g BW |
||
Administration: |
i.p.;every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.) |
||
Result: |
Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )